R. Okan Akar after graduating from the Molecular Biology and Genetics Department of Istanbul Kültür University, where he graduated with a second degree in 2017, completed his master's degree in Cancer Biology and Pharmacology at Istinye University. He is currently doing his doctorate in the molecular oncology program of Istinye University. He is also co-founder of Ovoboard Biyoteknoloji A.Ş. During his master’s, he worked as an intern at the Karolinska Institute Oncology-Pathology department in Sweden. He has been involved in laboratory studies for more than six years from the undergraduate level. He is working on molecular cancer pathways, anti-cancer drug discovery, and cell death. He is a member of the Molecular Cancer Research Association (MOKAD) and EACR (European Association for Cancer Research). He has published 10 articles in international journals. In addition to being a research assistant at Istinye University Medical Faculty Medical Biochemistry Department, he also works at Istinye University Molecular Cancer Research Center (ISUMKAM). His hobbies include science fiction-fantastic literature and basketball.
Araştırma Alanları
- Cancer Biology
- In ovo
- CAM assay
- Cell Death
- Molecular Biology
- Posttranslational Modifications
- Protein- Protein Interaction
Çalışma Alanları
- Fen Bilimleri ve Matematik Temel Alanı
- Moleküler Biyoloji ve Genetik
- Moleküler Biyoloji
- Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines, 2022
- Synthesis, DNA Binding and Cytotoxic Activity of Newcopper(II) Complexes of Trisubstituted Imidazoles, 2022
- Highly Promising Antitumor Agent of a Novel Platinum(II) Complex Bearing a Tetradentate Chelating Ligand, 2020
- A promising therapeutic combination for metastatic prostate cancer: Chloroquine as autophagy inhibitor and palladium(II) barbiturate complex, 2020
- The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells, 2019
- A novel 1,4-naphthoquinone-derived compound induces apoptotic cell death in breast cancer cells, 2019
- Key actors in cancer therapy: epigenetic modifiers, 2019
- Effect of p53 on Diclofenac and Ibuprofen-induced ROS generation-dependent apoptosis on PC3 prostate cancer cells,
- Diclofenac increased ROS generation to proceed EMT processes p53 independently in PC3 cells,
- A newly synthesized platinum complex as a potent antitumor drug candidate,
- MOKAD Genç Araştırmacı, 2019